Screener / SEC EDGAR /CIK 0001815442 /10-K filed Feb 26, 2026, compared with Feb 27, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Biotechnology

Kymera Therapeutics, Inc. KYMR

Compare with peers Embed
Earnings releases

Latest results release: Oct 29, 2026

8-K item 2.02, exhibit 99

What KYMR's management wrote with each quarter's results: the press release and, when the company files them, its prepared remarks or the call transcript. The call itself is not filed with SEC, so most quarters have the release only.

Read and search

Every release, in full · linked to sec.gov

Press release Oct 29, 2026 · EX-99.1

Kymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports

Open on SEC

Exhibit 99.1 Kymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports Positive Results from the KT-579 Phase 1 Healthy Volunteer Trial

KT-579 (IRF5) Phase 1 healthy volunteer data demonstrated deep, sustained IRF5 degradation, robust modulation of disease-relevant biomarkers and a favorable safety profile

Last patient completed last visit in KT-621 (STAT6) BROADEN2 Phase 2b AD trial, with topline data to be reported by year-end 2026

KT-621 BREADTH Phase 2b asthma trial ongoing, with topline data expected to be reported in late 2027

Well-capitalized with $1.6 billion in cash as of September 30, 2026, and runway into 2029

Company to hold video conference call and webcast today at 8:30 a.m. ET Watertown, Mass. (October 29, 2026) –Kymera Therapeutics, Inc.(NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today reported financial results for the third quarter ended September 30, 2026, and provided business highlights and updates on its pipeline.

“Kymera’s recent progress reinforces the opportunity across our portfolio and our ability to help shape a new era of differentiated oral medicines in immunology,” said Nello Mainolfi, PhD, Founder, President and CEO, Kymera Therapeutics. “With KT-621 and KT-579, we are advancing complementary immunoregulatory mechanisms that target distinct drivers of disease, with significant potential to address unmet needs across the current treatment landscape. The last patient has now completed their week 16 visit in our KT-621 BROADEN2 Phase 2b atopic dermatitis trial, and we plan to report topline data by year-end 2026. We also are planning to initiate our first Phase 3 AD trial by mid-2027, and report data from our BREADTH Phase 2b asthma trial in late 2027.”

Dr. Mainolfi continued, “The positive results from the Phase 1 healthy volunteer trial of KT-579, which we reported today, demonstrate strong translation of its preclinical pharmacology into humans and highlight its potential to modulate multiple core inflammatory pathways through a single oral mechanism. These findings exceed our expectations in terms of depth of degradation, safety and pathway suppression measured by downstream cytokines and gene transcripts. The results provide an important foundation as we advance KT-579, our 7thdegrader to enter the clinic, toward a study in lupus patients and explore the opportunity for targeting IRF5 in additional autoimmune diseases. Beyond these clinical programs, our research engine remains focused on unlocking novel biology and pursuing high value targets to build the next wave of oral medicines for patients who need effective, safe and convenient treatment options.”

KT-621 is an investigational, first-in-class, once daily, oral degrader of STAT6, the specific transcription factor responsible for IL-4/IL-13 signaling and the central driver of Type 2 inflammation. KT-621 is currently in Phase 2 clinical development inatopic dermatitis (AD) and asthma. KT-621 has the potential to transform treatment paradigms by offering a safe, effective, oral option for the more than 140 million patients worldwide living with Type 2 diseases, such as AD, asthma, chronic obstructive pulmonary disease (COPD), eosinophilic esophagitis (EoE), chronic rhinosinusitis with nasal polyps (CRSwNP), chronic spontaneous urticaria (CSU), prurigo nodularis (PN), and bullous pemphigoid (BP), among others.

In October 2026, the last patient received their final dose and completed the week 16 visit in the KT-621 BROADEN2 Phase 2b clinical trial in patients with moderate to severe AD. The Company plans to report topline data by year-end 2026. Subject to discussions with regulators, the Company expects to initiate the first Phase 3 trial in AD by mid-2027.

Enrollment is ongoing in the KT-621 BREADTH Phase 2b clinical trial in patients with moderate to severe eosinophilic asthma, with topline data expected to be reported in late 2027.

In September 2026, the Company presented data from the KT-621 BroADen Phase 1b clinical trial in AD across leading dermatology and respiratory forums, including posters at the European Academy of Dermatology and Venereology (EADV) and European Respiratory Society (ERS) Congresses.

KT-579 is an investigational, first-in-class, oral degrader of IRF5, a genetically validated transcription factor and master regulator of immunity. KT-579 has the potential to modulate multiple core inflammatory pathways through a single oral mechanism, offering a differentiated approach to serious autoimmune diseases where effective and well-tolerated oral therapies are needed, such as lupus, inflammatory bowel disease (IBD), Sjögren's, rheumatoid arthritis (RA) and others.

The Company today announced positive results from the completed first-in-human KT-579 Phase 1 healthy volunteer trial. The results met or exceeded study objectives and established strong proof of mechanism:

Pharmacokinetics and pharmacodynamics: KT-579 demonstrated a favorable plasma pharmacokinetic profile. Exposure increased with dose following single and multiple doses. Robust, sustained IRF5 degradation was observed following a single oral dose in the single ascending dose (SAD) portion of the trial. In the multiple ascending dose portion (MAD), KT-579 demonstrated deep, sustained IRF5 degradation in blood, with ≥90% median degradation across multiple dose levels with saturation of degradation by dose level 3 . Similar reductions in IRF5 levels were also observed in skin, demonstrating target degradation in tissue as well as blood.

Ex vivo-stimulated IRF5-dependent biomarkers: KT-579 showed robust suppression of disease-relevant blood biomarkers and significant downregulation of pathway gene transcripts, reflecting pharmacodynamic effects on the three immune pathways modulated by IRF5 including inflammatory cytokines, interferon (IFN) response, and B-cell biology. The inflammatory cytokine and IFN analysis using the median of all MAD dose cohorts showed inhibition of 88% of TNFα, 87% of IL-12/23p40, 94% of IL-1β, and 98% of IFNβ at Day 14. Gene-expression analyses also showed broad downregulation of inflammatory cytokine, interferon and B-cell associated genes, supporting the functional cytokine findings.

Safety and tolerability: The safety profile of KT-579 was comparable to placebo. There were no serious or severe adverse events (AEs) and no AEs leading to discontinuation. Very few mild treatment-related AEs were reported, and there was no dose-dependent pattern in treatment-emergent AEs. There were no clinically relevant changes in vital signs, laboratory tests or ECGs.

The KT-579 LUMORA Phase 1b trial in lupus patients is planned to start by early 2027. LUMORA is a randomized, double-blind, placebo-controlled trial testing KT-579 in approximately 30 adult patients with systemic lupus erythematosus dosed over 16 weeks. The key aim of this biomarker study is to demonstrate that KT-579 can modulate underlying disease biology with a favorable safety and tolerability profile while exploring potential clinical benefits.

The Company will present new preclinical data on KT-579 in an oral presentation at the American College of Rheumatology (ACR) Convergence conference, taking place November 6-11, 2026, in Orlando, FL. The presentation will highlight KT-579’s compelling profile, including significant activity both as a monotherapy and in combination with background therapies in preclinical lupus models.

The first-in-human Phase 1 clinical trial evaluating KT-485 (SAR447971) in healthy volunteers and hidradenitis suppurativa patients is ongoing. Under the collaboration, Sanofi is leading development, regulatory and commercial efforts for the program. KT-485 is a potent, selective, oral second-generation IRAK4 degrader with the potential to offer a novel approach for a range of chronic immuno-inflammatory diseases.

Gilead Sciences is advancing KT-200 in IND-enabling studies to support an IND filing in 2027. KT-200 is a first-in-class, oral CDK2 molecular glue degrader development candidate discovered and characterized by Kymera and exclusively licensed to Gilead. KT-200 has the potential to improve the standard of care for patients with breast cancer and other solid tumors.

Leveraging its unique target selection strategy, proven small molecule discovery capabilities, and deep development expertise, the Company continues to advance an early pipeline of novel oral programs with a goal to deliver at least one new development candidate per year.

In July 2026, the Company appointed Terence Rooney, MD, as Chief Medical Officer and Elizabeth Laws, PhD, as Senior Vice President, Global STAT6 Development Program Leader, strengthening its clinical development leadership to support the continued advancement of Kymera’s oral immunology portfolio.

Collaboration Revenues:There were no collaboration revenues for the third quarter of 2026 compared to $2.8 million for the third quarter of 2025. Collaboration revenues recognized in the third quarter of 2025 were all attributable to the Company’s collaboration with Gilead. The Company does not expect to recognize additional collaboration revenue in 2026.

Research and Development Expenses:Research and development expenses were $128.5 million for the third quarter of 2026 compared to $74.1 million for the third quarter of 2025. This increase was primarily due to increased expenses related to the investment in the Company’s STAT6 program, platform and discovery programs, as well as costs related to continued growth in the research and development organization. Stock based compensation expenses included in R&D were $10.9 million and $8.4 million for the third quarters of 2026 and 2025, respectively.

General and Administrative Expenses:General and administrative expenses were $18.7 million for the third quarter of 2026 compared to $17.3 million for the third quarter of 2025. The increase was primarily due to an increase in legal and professional service fees in support of the Company’s growth and an increase in personnel, facility, occupancy, and other expenses to support growth as a public company. Stock based compensation expenses included in G&A were $7.9 million and $7.4 million for the third quarters of 2026 and 2025, respectively.

Net Loss:Net loss was $132.0 million for the third quarter of 2026 compared to $82.2 million for the third quarter of 2025.

Cash and Cash Equivalents:As of September 30, 2026, Kymera had $1.6 billion in cash, cash equivalents and investments. Kymera expects that its cash balance will provide the Company with a cash runway into 2029 beyond multiple clinical inflection points in its pipeline.

Kymera will host a video conference call today, October 29, 2026, at 8:30 a.m. ET. To join the call please usethis linkto register. A live webcast of the event will be available underNews and Eventsin the Investors section of the Company’s website atwww.kymeratx.com. A replay of the webcast will be archived and available following the event.

About Kymera TherapeuticsKymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visitwww.kymeratx.comor follow us onXorLinkedIn.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements about our expectations regarding strategy, business plans and objectives on the development of our clinical and preclinical pipeline, including the therapeutic potential, clinical benefits and safety thereof, the KT-485/SAR447971 and KT-200 programs, and Kymera’s financial condition and expected cash runway into 2029. The words "may," "might," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "seek," "predict," "future," "project," "potential," "continue," "target," “upcoming” and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from any forward-looking statements contained in this press release, including, without limitation, risks associated with: the risk that preclinical and clinical data, including the results from the Phase 1 trials of KT-621 and KT-579, are not predictive of, may be inconsistent with, or more favorable than, data generated from future or ongoing clinical trials of the same product candidate, uncertainties inherent in the initiation, timing and design of future clinical trials, the availability and timing of data from ongoing and future clinical trials and the results of such trials, the ability to successfully demonstrate the safety and efficacy of drug candidates, the timing and outcome of planned interactions with and submissions to regulatory authorities, the availability of funding sufficient for our operating expenses and capital expenditure requirements, the unexpected emergence of adverse events or other undesirable side effects during preclinical and clinical development, and other factors. These risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in the most recent Quarterly Report on Form 10-Q and in subsequent filings with the SEC. In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. We explicitly disclaim any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

KYMERA THERAPEUTICS, INC. Consolidated Balance Sheets (In thousands, except share and per share amounts) (Unaudited) September 30, December 31, 2026 2025 Assets Cash, cash equivalents and marketable $ 1,645,883 $ 1,619,434 securities Property and equipment, 38,242 43,175 net Right-of-use assets, 40,444 42,351 operating lease Other assets 42,700 37,852 Total assets $ 1,767,269 $ 1,742,812 Liabilities and Stockholders’ Equity Accrued expenses $ 63,315 $ 42,274 Operating lease 74,626 78,975 liabilities Other liabilities 14,801 41,899 Total liabilities 152,742 163,148 Total stockholders’ 1,614,527 1,579,664 equity Total liabilities, preferred stock and $ 1,767,269 $ 1,742,812 stockholders’ equity

KYMERA THERAPEUTI… INC. Consolidat… Statements of Operations and Comprehens… Loss (In thousands, except share and per share amounts) (Unaudited) Three Months Nine Months Ended Ended September September 30, 30, 2026 2025 2026 2025 Collaborat… $ $ $ $ Revenue — 2,764 99,365 36,341 Operating expenses: Research $ $ $ $ and 128,509 74,094 346,152 232,737 development General and 18,723 17,336 60,207 51,252 administra… Impairment of — 3,855 — 3,855 long-lived assets Total operating 147,232 95,285 406,359 287,844 expenses Loss from -147,232 -92,521 -306,994 -251,503 operations Other income (expense): Interest and other 15,295 10,444 44,753 27,413 income Interest and other -62 -98 -203 -280 expense Total other 15,233 10,346 44,550 27,133 income Net loss attributab… $ $ $ $ to common (131,999) (82,175) (262,444) (224,370) stockholde… Net loss per share attributab… to $ $ $ $ common (1.32) (0.94) (2.66) (2.71) stockholde… basic and diluted Weighted average common stocks 100,097,242 87,300,286 98,612,278 82,653,142 outstandin… basic and diluted

Full text with the tables
                                                                    Exhibit 99.1
 Kymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports 
        Positive Results from the KT-579 Phase 1 Healthy Volunteer Trial        
                                                                                
 KT-579 (IRF5) Phase 1 healthy volunteer data demonstrated deep, sustained IRF5 
 degradation, robust modulation of disease-relevant biomarkers and a favorable  
                                 safety profile                                 
                                                                                
 KT-579 LUMORA Phase 1b trial in lupus patients planned to start by early 2027  
                                                                                
Last patient completed last visit in KT-621 (STAT6) BROADEN2 Phase 2b AD trial, 
               with topline data to be reported by year-end 2026                
                                                                                
 KT-621 BREADTH Phase 2b asthma trial ongoing, with topline data expected to be 
                             reported in late 2027                              
                                                                                
Well-capitalized with $1.6 billion in cash as of September 30, 2026, and runway 
                                   into 2029                                    
                                                                                
    Company to hold video conference call and webcast today at 8:30 a.m. ET     
Watertown, Mass. (October 29, 2026) –Kymera Therapeutics, Inc.(NASDAQ: KYMR), a 
clinical-stage biopharmaceutical company advancing a new class of oral small    
molecule degrader medicines for immunological diseases, today reported financial
results for the third quarter ended September 30, 2026, and provided business   
highlights and updates on its pipeline.                                         
                                                                                
“Kymera’s recent progress reinforces the opportunity across our portfolio and   
our ability to help shape a new era of differentiated oral medicines in         
immunology,” said Nello Mainolfi, PhD, Founder, President and CEO, Kymera       
Therapeutics. “With KT-621 and KT-579, we are advancing complementary           
immunoregulatory mechanisms that target distinct drivers of disease, with       
significant potential to address unmet needs across the current treatment       
landscape. The last patient has now completed their week 16 visit in our KT-621 
BROADEN2 Phase 2b atopic dermatitis trial, and we plan to report topline data by
year-end 2026. We also are planning to initiate our first Phase 3 AD trial by   
mid-2027, and report data from our BREADTH Phase 2b asthma trial in late 2027.” 
                                                                                
Dr. Mainolfi continued, “The positive results from the Phase 1 healthy volunteer
trial of KT-579, which we reported today, demonstrate strong translation of its 
preclinical pharmacology into humans and highlight its potential to modulate    
multiple core inflammatory pathways through a single oral mechanism. These      
findings exceed our expectations in terms of depth of degradation, safety and   
pathway suppression measured by downstream cytokines and gene transcripts. The  
results provide an important foundation as we advance KT-579, our 7thdegrader to
enter the clinic, toward a study in lupus patients and explore the opportunity  
for targeting IRF5 in additional autoimmune diseases. Beyond these clinical     
programs, our research engine remains focused on unlocking novel biology and    
pursuing high value targets to build the next wave of oral medicines for        
patients who need effective, safe and convenient treatment options.”            
                                                                                
Business Highlights, Recent Developments and Upcoming Milestones                
                                                                                
STAT6 Degrader Program                                                          
                                                                                
KT-621 is an investigational, first-in-class, once daily, oral degrader of      
STAT6, the specific transcription factor responsible for IL-4/IL-13 signaling   
and the central driver of Type 2 inflammation. KT-621 is currently in Phase 2   
clinical development inatopic dermatitis (AD) and asthma. KT-621 has the        
potential to transform treatment paradigms by offering a safe, effective, oral  
option for the more than 140 million patients worldwide living with Type 2      
diseases, such as AD, asthma, chronic obstructive pulmonary disease (COPD),     
eosinophilic esophagitis (EoE), chronic rhinosinusitis with nasal polyps        
(CRSwNP), chronic spontaneous urticaria (CSU), prurigo nodularis (PN), and      
bullous pemphigoid (BP), among others.                                          
                                                                                
In October 2026, the last patient received their final dose and completed the   
week 16 visit in the KT-621 BROADEN2 Phase 2b clinical trial in patients with   
moderate to severe AD. The Company plans to report topline data by year-end     
2026. Subject to discussions with regulators, the Company expects to initiate   
the first Phase 3 trial in AD by mid-2027.                                      
                                                                                
Enrollment is ongoing in the KT-621 BREADTH Phase 2b clinical trial in patients 
with moderate to severe eosinophilic asthma, with topline data expected to be   
reported in late 2027.                                                          
                                                                                
In September 2026, the Company presented data from the KT-621 BroADen Phase 1b  
clinical trial in AD across leading dermatology and respiratory forums,         
including posters at the European Academy of Dermatology and Venereology (EADV) 
and European Respiratory Society (ERS) Congresses.                              
                                                                                
IRF5 Degrader Program                                                           
                                                                                
KT-579 is an investigational, first-in-class, oral degrader of IRF5, a          
genetically validated transcription factor and master regulator of immunity.    
KT-579 has the potential to modulate multiple core inflammatory pathways through
a single oral mechanism, offering a differentiated approach to serious          
autoimmune diseases where effective and well-tolerated oral therapies are       
needed, such as lupus, inflammatory bowel disease (IBD), Sjögren's, rheumatoid  
arthritis (RA) and others.                                                      
                                                                                
The Company today announced positive results from the completed first-in-human  
KT-579 Phase 1 healthy volunteer trial. The results met or exceeded study       
objectives and established strong proof of mechanism:                           
                                                                                
Pharmacokinetics and pharmacodynamics: KT-579 demonstrated a favorable plasma   
pharmacokinetic profile. Exposure increased with dose following single and      
multiple doses. Robust, sustained IRF5 degradation was observed following a     
single oral dose in the single ascending dose (SAD) portion of the trial. In the
multiple ascending dose portion (MAD), KT-579 demonstrated deep, sustained IRF5 
degradation in blood, with ≥90% median degradation across multiple dose levels  
with saturation of degradation by dose level 3 . Similar reductions in IRF5     
levels were also observed in skin, demonstrating target degradation in tissue as
well as blood.                                                                  
                                                                                
Ex vivo-stimulated IRF5-dependent biomarkers: KT-579 showed robust suppression  
of disease-relevant blood biomarkers and significant downregulation of pathway  
gene transcripts, reflecting pharmacodynamic effects on the three immune        
pathways modulated by IRF5 including inflammatory cytokines, interferon (IFN)   
response, and B-cell biology. The inflammatory cytokine and IFN analysis using  
the median of all MAD dose cohorts showed inhibition of 88% of TNFα, 87% of     
IL-12/23p40, 94% of IL-1β, and 98% of IFNβ at Day 14. Gene-expression analyses  
also showed broad downregulation of inflammatory cytokine, interferon and B-cell
associated genes, supporting the functional cytokine findings.                  
                                                                                
Safety and tolerability: The safety profile of KT-579 was comparable to placebo.
There were no serious or severe adverse events (AEs) and no AEs leading to      
discontinuation. Very few mild treatment-related AEs were reported, and there   
was no dose-dependent pattern in treatment-emergent AEs. There were no          
clinically relevant changes in vital signs, laboratory tests or ECGs.           
                                                                                
The KT-579 LUMORA Phase 1b trial in lupus patients is planned to start by early 
2027. LUMORA is a randomized, double-blind, placebo-controlled trial testing    
KT-579 in approximately 30 adult patients with systemic lupus erythematosus     
dosed over 16 weeks. The key aim of this biomarker study is to demonstrate that 
KT-579 can modulate underlying disease biology with a favorable safety and      
tolerability profile while exploring potential clinical benefits.               
                                                                                
The Company will present new preclinical data on KT-579 in an oral presentation 
at the American College of Rheumatology (ACR) Convergence conference, taking    
place November 6-11, 2026, in Orlando, FL. The presentation will highlight      
KT-579’s compelling profile, including significant activity both as a           
monotherapy and in combination with background therapies in preclinical lupus   
models.                                                                         
                                                                                
Partnered Programs & Research                                                   
                                                                                
The first-in-human Phase 1 clinical trial evaluating KT-485 (SAR447971) in      
healthy volunteers and hidradenitis suppurativa patients is ongoing. Under the  
collaboration, Sanofi is leading development, regulatory and commercial efforts 
for the program. KT-485 is a potent, selective, oral second-generation IRAK4    
degrader with the potential to offer a novel approach for a range of chronic    
immuno-inflammatory diseases.                                                   
                                                                                
Gilead Sciences is advancing KT-200 in IND-enabling studies to support an IND   
filing in 2027. KT-200 is a first-in-class, oral CDK2 molecular glue degrader   
development candidate discovered and characterized by Kymera and exclusively    
licensed to Gilead. KT-200 has the potential to improve the standard of care for
patients with breast cancer and other solid tumors.                             
                                                                                
Leveraging its unique target selection strategy, proven small molecule discovery
capabilities, and deep development expertise, the Company continues to advance  
an early pipeline of novel oral programs with a goal to deliver at least one new
development candidate per year.                                                 
                                                                                
Corporate                                                                       
                                                                                
In July 2026, the Company appointed Terence Rooney, MD, as Chief Medical Officer
and Elizabeth Laws, PhD, as Senior Vice President, Global STAT6 Development     
Program Leader, strengthening its clinical development leadership to support the
continued advancement of Kymera’s oral immunology portfolio.                    
                                                                                
Financial Results                                                               
                                                                                
Collaboration Revenues:There were no collaboration revenues for the third       
quarter of 2026 compared to $2.8 million for the third quarter of 2025.         
Collaboration revenues recognized in the third quarter of 2025 were all         
attributable to the Company’s collaboration with Gilead. The Company does not   
expect to recognize additional collaboration revenue in 2026.                   
                                                                                
Research and Development Expenses:Research and development expenses were $128.5 
million for the third quarter of 2026 compared to $74.1 million for the third   
quarter of 2025. This increase was primarily due to increased expenses related  
to the investment in the Company’s STAT6 program, platform and discovery        
programs, as well as costs related to continued growth in the research and      
development organization. Stock based compensation expenses included in R&D were
$10.9 million and $8.4 million for the third quarters of 2026 and 2025,         
respectively.                                                                   
                                                                                
General and Administrative Expenses:General and administrative expenses were    
$18.7 million for the third quarter of 2026 compared to $17.3 million for the   
third quarter of 2025. The increase was primarily due to an increase in legal   
and professional service fees in support of the Company’s growth and an increase
in personnel, facility, occupancy, and other expenses to support growth as a    
public company. Stock based compensation expenses included in G&A were $7.9     
million and $7.4 million for the third quarters of 2026 and 2025, respectively. 
                                                                                
Net Loss:Net loss was $132.0 million for the third quarter of 2026 compared to  
$82.2 million for the third quarter of 2025.                                    
                                                                                
Cash and Cash Equivalents:As of September 30, 2026, Kymera had $1.6 billion in  
cash, cash equivalents and investments. Kymera expects that its cash balance    
will provide the Company with a cash runway into 2029 beyond multiple clinical  
inflection points in its pipeline.                                              
                                                                                
Event Details                                                                   
                                                                                
Kymera will host a video conference call today, October 29, 2026, at 8:30 a.m.  
ET. To join the call please usethis linkto register. A live webcast of the event
will be available underNews and Eventsin the Investors section of the Company’s 
website atwww.kymeratx.com. A replay of the webcast will be archived and        
available following the event.                                                  
                                                                                
About Kymera TherapeuticsKymera is a clinical-stage biotechnology company       
pioneering the field of targeted protein degradation (TPD) to develop medicines 
that address critical health problems and have the potential to dramatically    
improve patients’ lives. Kymera is deploying TPD to address disease targets and 
pathways inaccessible with conventional therapeutics. Having advanced the first 
degrader into the clinic for immunological diseases, Kymera is focused on       
building an industry-leading pipeline of oral small molecule degraders to       
provide a new generation of convenient, highly effective therapies for patients 
with these conditions. Founded in 2016, Kymera has been recognized as one of    
Boston’s top workplaces for the past several years. For more information about  
our science, pipeline and people, please visitwww.kymeratx.comor follow us      
onXorLinkedIn.                                                                  
                                                                                
Cautionary Note Regarding Forward-Looking Statements                            
                                                                                
This press release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995, as amended, including, without
limitation, implied and express statements about our expectations regarding     
strategy, business plans and objectives on the development of our clinical and  
preclinical pipeline, including the therapeutic potential, clinical benefits and
safety thereof, the KT-485/SAR447971 and KT-200 programs, and Kymera’s financial
condition and expected cash runway into 2029. The words "may," "might," "will," 
"could," "would," "should," "expect," "plan," "anticipate," "intend," "believe,"
"estimate," "seek," "predict," "future," "project," "potential," "continue,"    
"target," “upcoming” and similar words or expressions are intended to identify  
forward-looking statements, although not all forward-looking statements contain 
these identifying words. Any forward-looking statements in this press release   
are based on management's current expectations and beliefs and are subject to a 
number of risks, uncertainties and important factors that may cause actual      
events or results to differ materially from any forward-looking statements      
contained in this press release, including, without limitation, risks associated
with: the risk that preclinical and clinical data, including the results from   
the Phase 1 trials of KT-621 and KT-579, are not predictive of, may be          
inconsistent with, or more favorable than, data generated from future or ongoing
clinical trials of the same product candidate, uncertainties inherent in the    
initiation, timing and design of future clinical trials, the availability and   
timing of data from ongoing and future clinical trials and the results of such  
trials, the ability to successfully demonstrate the safety and efficacy of drug 
candidates, the timing and outcome of planned interactions with and submissions 
to regulatory authorities, the availability of funding sufficient for our       
operating expenses and capital expenditure requirements, the unexpected         
emergence of adverse events or other undesirable side effects during preclinical
and clinical development, and other factors. These risks and uncertainties are  
described in greater detail in the section entitled "Risk Factors" in the most  
recent Quarterly Report on Form 10-Q and in subsequent filings with the SEC. In 
addition, any forward-looking statements represent our views only as of today   
and should not be relied upon as representing our views as of any subsequent    
date. We explicitly disclaim any obligation to update any forward-looking       
statements. No representations or warranties (expressed or implied) are made    
about the accuracy of any such forward-looking statements.                      
                                                                                
  KYMERA THERAPEUTICS,                                                          
  INC.                                                                          
  Consolidated Balance                                                          
  Sheets                                                                        
  (In thousands, except                                                         
  share and per                                                                 
  share amounts)                                                                
  (Unaudited)                                                                   
                                       September 30,              December 31,  
                                                2026                      2025  
  Assets                                                                        
  Cash, cash equivalents                                                        
  and marketable                $          1,645,883      $          1,619,434  
  securities                                                                    
  Property and equipment,                     38,242                    43,175  
  net                                                                           
  Right-of-use assets,                        40,444                    42,351  
  operating lease                                                               
  Other assets                                42,700                    37,852  
  Total assets                  $          1,767,269      $          1,742,812  
  Liabilities and                                                               
  Stockholders’ Equity                                                          
  Accrued expenses            $               63,315    $               42,274  
  Operating lease                             74,626                    78,975  
  liabilities                                                                   
  Other liabilities                           14,801                    41,899  
  Total liabilities                          152,742                   163,148  
  Total stockholders’                      1,614,527                 1,579,664  
  equity                                                                        
  Total liabilities,                                                            
  preferred stock and           $          1,767,269      $          1,742,812  
  stockholders’ equity                                                          
                                                                                
                                                                                
  KYMERA                                                                        
  THERAPEUTI…                                                                   
  INC.                                                                          
  Consolidat…                                                                   
  Statements                                                                    
  of                                                                            
  Operations                                                                    
  and                                                                           
  Comprehens…                                                                   
  Loss                                                                          
  (In                                                                           
  thousands,                                                                    
  except                                                                        
  share and                                                                     
  per                                                                           
  share                                                                         
  amounts)                                                                      
  (Unaudited)                                                                   
                 Three Months                     Nine Months                   
                        Ended                           Ended                   
                    September                       September                   
                          30,                             30,                   
                         2026            2025            2026             2025  
  Collaborat…               $               $               $                $  
  Revenue                   —           2,764          99,365           36,341  
  Operating                                                                     
  expenses:                                                                     
  Research                  $               $               $                $  
  and                 128,509          74,094         346,152          232,737  
  development                                                                   
  General and          18,723          17,336          60,207           51,252  
  administra…                                                                   
  Impairment                                                                    
  of                        —           3,855               —            3,855  
  long-lived                                                                    
  assets                                                                        
  Total                                                                         
  operating           147,232          95,285         406,359          287,844  
  expenses                                                                      
  Loss from          -147,232         -92,521        -306,994         -251,503  
  operations                                                                    
  Other                                                                         
  income                                                                        
  (expense):                                                                    
  Interest                                                                      
  and other            15,295          10,444          44,753           27,413  
  income                                                                        
  Interest                                                                      
  and other               -62             -98            -203             -280  
  expense                                                                       
  Total other          15,233          10,346          44,550           27,133  
  income                                                                        
  Net loss                                                                      
  attributab…               $               $               $                $  
  to common         (131,999)        (82,175)       (262,444)        (224,370)  
  stockholde…                                                                   
  Net loss                                                                      
  per share                                                                     
  attributab…                                                                   
  to                        $               $               $                $  
  common               (1.32)          (0.94)          (2.66)           (2.71)  
  stockholde…                                                                   
  basic and                                                                     
  diluted                                                                       
  Weighted                                                                      
  average                                                                       
  common                                                                        
  stocks          100,097,242      87,300,286      98,612,278       82,653,142  
  outstandin…                                                                   
  basic and                                                                     
  diluted                                                                       
                                                                                
Investor Contact:                                                               
                                                                                
Justine Koenigsberg                                                             
                                                                                
[email protected]                                                          
                                                                                
857-285-5300                                                                    
                                                                                
Media Contact:                                                                  
                                                                                
Matthew Henson                                                                  
                                                                                
[email protected]                                                              
                                                                                
857-285-5300                                                                    

Sources

The 8-K item 2.02 filings (SEC EDGAR) and their EX-99 exhibits: the results release and, when filed, prepared remarks or the call transcript.

Also

Said vs did: the targets in these releases against what was then reported. Filings: every filing.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/KYMR/export.csv") into a cell.

Next:Presentations
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.